Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DBH | P09172 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30206331 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2SIGMAR1POLBKMT2AKCNH2 | |
| SCHEMBL545015 | 0.81 | KCNH2 (0.41) | KCNH2CYP2D6DRD4 | |
| SCHEMBL28184444 | 0.78 | HRH3 (0.61) | SMN1; SMN2SIGMAR1POLBKMT2ACYP2C9 | |
| SCHEMBL12665901 | 0.74 | ALDH1A1 (0.47) | POLBKCNH2CYP2D6 | |
| SCHEMBL20484955 | 0.74 | HIF1A (0.44) | SIGMAR1KMT2AKCNH2CYP2D6 | |
| SCHEMBL25699463 | 0.74 | ALDH1A1 (0.44) | SMN1; SMN2GAAKCNH2 | |
| SCHEMBL114537 | 0.73 | CYP2A13 (0.43) | SIGMAR1POLBKCNH2CYP2C9HSD17B10 | |
| SCHEMBL4151517 | 0.73 | SMN1; SMN2 (0.72) | SMN1; SMN2SIGMAR1POLBCYP2D6CYP2C19 | |
| SCHEMBL16076176 | 0.71 | HRH3 (0.59) | SMN1; SMN2SIGMAR1POLBKMT2ACYP2C9 | |
| SCHEMBL30630159 | 0.71 | KDM4E (0.55) | SIGMAR1KCNH2PRMT5WDR77CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424870-B1 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2015-12-16 | — | — | EP | disclosed |
| EP-2424870-B1 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2015-12-16 | — | — | EP | disclosed |
| US-8110566-B2 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2012-02-07 | — | — | US | disclosed |
| US-8110566-B2 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2012-02-07 | — | — | US | disclosed |
| US-8110566-B2 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2012-02-07 | — | — | US | disclosed |
| WO-2010125390-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | MC1R, MC2R, MC3R | DBH 331/4885SMN1; SMN2 2550/4885GAA 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.